Drug Profile
Research programme: autoimmune disorder therapeutics - Amgen/Array BioPharma
Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Amgen; Array BioPharma
- Developer Array BioPharma
- Class
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 18 Jul 2017 Early research in Autoimmune disorders in USA (unspecified route)